Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002317 · ClinicalTrials.gov registry record · NA
A Study of Trimetrexate Plus Leucovorin in Children With Pneumocystis Carinii Pneumonia
A NA study of HIV Infections and Pneumonia, Pneumocystis Carinii, sponsored by U.S. Bioscience.
- Completed
- Registry status
- NA
- Development phase
- 1
- Study location
NCT00002317: Completed NA study of HIV Infections and Pneumonia, Pneumocystis Carinii, sponsored by U.S. Bioscience.
NCT00002317 is a NA study of HIV Infections and Pneumonia, Pneumocystis Carinii that has completed, run by U.S. Bioscience. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002317, a NA study of HIV Infections and Pneumonia, Pneumocystis Carinii, has completed, sponsored by U.S. Bioscience.
- COMPLETED
- Registry status
- NA
- Development phase
- 1
- Study location
Study Summary
To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in pediatric patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or parenteral pentamidine).
Conditions Studied
Interventions
- DRUG Leucovorin calcium
- DRUG Trimetrexate glucuronate
Study Locations (1)
Pennsylvania
- United States Bioscience Inc - West Conshohocken
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002317 record still lists
NCT00002317 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Leucovorin calcium is the first listed.
NCT00002317 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00002317 about?
NCT00002317 is a clinical study titled "A Study of Trimetrexate Plus Leucovorin in Children With Pneumocystis Carinii Pneumonia". To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in pediatric patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or parenteral pentamidine).
What is the current status of trial NCT00002317?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002317 study?
This clinical trial studies the following conditions: HIV Infections, Pneumonia, Pneumocystis Carinii.
What interventions are being tested in trial NCT00002317?
The interventions under investigation include: Leucovorin calcium (DRUG), Trimetrexate glucuronate (DRUG).
Who is sponsoring clinical trial NCT00002317?
This trial is sponsored by U.S. Bioscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002317 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA